Abstract
Objective: to study the efficacy and safety of antiviraltherapy for influenza and acute respiratory viral infection with Kagocel in children in a hospital. Materials and methods: in the observational study included 80 children aged 3 to 11 years, hospitalized with symptoms of influenza and acute respiratory viral infection. The etiological confirmation of the diagnosis was carried out by the PCR method based onthe study of nasal swabs.The drug Kagocel was administered according to the instructions for use during the first 24 hours of hospitalization.The analysis of the virus release after the course of therapy with Kagocel (at 5–6 days from the beginning of treatment) was carried out only in patients with verified influenza and acute respiratory viral infection. Results: the dominant influence of viruses in the development of acute respiratory infections in children aged 3 to 11 years in the period of rising morbidity in St. Petersburg from September 2015 to May 2016. At the same time, 25% of the total number of patients were sick with influenza A and/or B. There was a significant decrease in fever to the third day (p <0,001) and normalization of body temperature from the fourth day after the beginning of therapy with Kagocel in the general group and in patients with confirmed influenza diagnosis. The intoxication syndrome, most pronounced with the flu, was mostly stopped by the fourth day(р<0,001). Catarrhalsyndrome, prevalent in the general group of acute respiratory viral infection, had longer periods of clinical manifestation and against the background of the therapy completely eliminated to the third or seventh day of therapy.Negative PCR results after the course of Kagocel therapy were established in 57,1% of the total group of patients. Among all detected viruses, the most typical is the absence of repeated isolation of influenza B and A viruses, PC virus (86% and 53,8%, 71,4%, respectively), the elimination of rhinoviruses was less frequent (33,3%). Conclusion: according to the results of the study, the effectiveness of therapy with the inclusion of the drug Kagocel in relieving fever by 3–4 days of treatment, as well as intoxication syndrome by 5–6 days in patients with acute respiratory viral infections, including patients with influenza, has been established. Negative results of PCR at the time of completion of therapy occurred mainly in patients with influenza A and B, PC infection. No adverse events were noted.
Highlights
Objective: to study the efficacy and safety of antiviral therapy for influenza and acute respiratory viral infection with Kagocel in children in a hospital
При этом 20 пациентов были больны гриппом А и В (25% от общего числа), что превышало среднегодовые значения предыдущих лет (12– 16%)
Заключение Особенностью этиологической структуры острой респираторной инфекции в период с сентября 2015 г. по май 2016 г. у госпитализированных детей была большая доля гриппа А и В (25%), что отразило имевший место в Санкт-Петербурге подъем заболеваемости гриппом А (H1N1)pdm09
Summary
Objective: to study the efficacy and safety of antiviral therapy for influenza and acute respiratory viral infection with Kagocel in children in a hospital. Это приводит к необоснованному назначению специфических противогриппозных препаратов у больных с ОРВИ негриппозной этиологии, а также снижает эффективность противовирусной терапии гриппа ингибиторами М2-каналов вирусов гриппа А и ингибиторами нейраминидазы у пациентов, в том числе с сочетанной вирусно-вирусной этиологией из-за нечувствительности к ним респираторных негриппозных вирусов. Анализ вирусовыделения после курса терапии препаратом Кагоцел проводили только у пациентов с верифицированными гриппом и ОРВИ негриппозной этиологии (на 5–6-е сутки от начала лечения).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.